Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Jun 25 · above the Ichimoku cloud · RSI 97 (overbought) · MACD below its signal · at its 52-week high
None of the 29 investors followed here reported a position in SARTF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SARTF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SARTF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.6 | 0.0 | -6.2 | 6.9 | -6.3 | 0.0 | 0.0 | 14.6 | 0.0 | +8.4% | ||
| 2025 | 32.3 | -19.9 | -8.6 | 18.1 | -4.9 | -3.1 | -4.9 | 2.0 | -3.3 | 16.5 | -7.1 | 14.5 | +22.3% |
| 2024 | 1.5 | 1.0 | 2.6 | -17.3 | -15.4 | -7.9 | -9.0 | 29.8 | -3.9 | -10.2 | -1.0 | -5.8 | −35.4% |
| 2023 | 5.5 | -3.4 | -5.5 | -7.8 | -7.4 | -5.1 | 19.0 | -6.1 | -7.7 | -25.6 | 16.6 | 18.3 | −17.5% |
| 2022 | -5.5 | -23.4 | -0.3 | -13.0 | 13.4 | -12.5 | 20.8 | 1.3 | -27.1 | -9.6 | 0.7 | 28.4 | −34.9% |
| 2021 | 1.2 | 12.0 | -6.6 | 4.6 | -12.4 | 14.6 | 23.1 | 36.5 | -0.4 | -19.6 | -4.8 | -11.4 | +26.4% |
| 2020 | 17.4 | -3.0 | -1.5 | 25.0 | 0.0 | -2.8 | 19.4 | 8.8 | -2.6 | 0.0 | 16.5 | 6.3 | +113.5% |
| 2019 | 0.1 | 0.0 | 12.5 | 5.7 | 9.8 | -2.4 | 12.3 | -6.3 | -8.8 | 0.0 | 0.0 | 19.9 | +46.6% |
| 2018 | 0.0 | 27.4 | 5.4 | 0.0 | 0.0 | 0.0 | 0.0 | 23.3 | 0.0 | -16.8 | 8.2 | 0.0 | +49.1% |
| 2017 | 0.0 | 0.0 | 14.8 | -7.7 | 9.6 | 4.1 | -4.5 | 5.7 | 1.4 | -7.3 | 1.1 | 0.0 | +16.1% |
| 2016 | -2.4 | 0.0 | 0.0 | 3.0 | -10.0 | 1.1 | 6.9 | 5.2 | -4.3 | 0.0 | 0.0 | 0.0 | −1.5% |
| 2015 | 0.0 | 0.0 | 0.0 | 28.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 109.0 | +168.7% |
| 2014 | 0.0 | 0.0 | 0.0 | 0.0 | 9.6 | 0.0 | 0.0 | 0.0 | 0.0 | -5.8 | 0.0 | 0.0 | +3.2% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 320.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +320.7% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2011 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.